Please assess the completion status of the following clinical trial:

Trial Title: Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-~Pregnant Women aged 14 years and over at ≥ 24 weeks' viable gestation who will undergo unscheduled/non-elective cesareans with either:~1. Labor (spontaneous or induced): active labor (ongoing contractions and at least 4cm dilated or contractions for at least 4 hours with documented cervical change of ≥1cm dilatation or ≥50% effacement), or~2. Membrane rupture (standardized to duration of at least 4 hours prior to randomization).~Exclusion Criteria:~* Patient unwilling or unable to provide consent~* Multiple pregnancy~* Known azithromycin (or other macrolide) allergy~* Vaginal delivery~* Elective or scheduled cesarean prior to labor or membrane rupture.~* Azithromycin, erythromycin or other macrolide antibiotic use within 7 days of enrollment.~* Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization.~* Patient is unable or unlikely to follow-up after delivery (e.g. no prenatal care or a non-resident patient)~* Fetal demise or major congenital anomaly~* Significant liver disease defined as known cirrhosis or elevated transaminases of at least 3-fold upper limit of normal~* Significant renal disease defined as serum creatinine known to be \>2.0 mg/dl or on dialysis.~* Active congestive heart failure (EF\<45%) or pulmonary edema~* Active diarrhea at time of delivery~* Any patient with significant electrolyte abnormalities such as hypokalemia or hypocalcemia~* Any patient with structural heart disease or arrhythmias, or taking any medications known to prolong the QT interval~* Patient currently being treated with efavirenz, nelfinavir or fluconazole

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo and standard of care (Type: PLACEBO_COMPARATOR): 250 cc normal saline
- Azithromycin and Standard of care (Type: EXPERIMENTAL): 500 mg Azithromycin in 250 cc normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).